Clinical Trials of Oncolytic Viruses in Breast Cancer

被引：19

作者：

Carter, Mary E. ^{[1
]}

Koch, Andre ^{[1
]}

Lauer, Ulrich M. ^{[2
]}

Hartkopf, Andreas D. ^{[1
]}

机构：

[1] Univ Tubingen, Dept Obstet & Gynaecol, Tubingen, Germany

[2] Univ Tubingen, Dept Internal Med Med Oncol & Pneumol 8, Tubingen, Germany

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

oncolytic virus; virotherapy; breast cancer; clinical trials; review; HERPES-SIMPLEX-VIRUS; PHASE-I TRIAL; YEAST CYTOSINE DEAMINASE; NEWCASTLE-DISEASE VIRUS; DOUBLE-BLIND; IMMUNE-RESPONSES; III TRIAL; GM-CSF; THERAPY; REPLICATION;

D O I：

10.3389/fonc.2021.803050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of oncolytic viruses used in clinical trials; (i) oncolytic viruses with natural anti-neoplastic properties; (ii) oncolytic viruses designed for tumor-selective replication; (iii) oncolytic viruses modified to activate the immune system. Currently, fourteen different oncolytic viruses have been investigated in eighteen published clinical trials. These trials demonstrate that oncolytic viruses are well tolerated and safe for use in patients and display clinical activity. However, these trials mainly studied a small number of patients with different advanced tumors including some with breast cancer. Future trials should focus on breast cancer and investigate optimal routes of administration, occurrence of neutralizing antibodies, viral gene expression, combinations with other antineoplastic therapies, and identify subtypes that are particularly suitable for oncolytic virotherapy.

引用

页数：13

共 94 条

[1] Newcastle disease and other avian paramyxoviruses [J].

Alexander, DJ .

REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES, 2000, 19 (02) :443-462

[2] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[3] The viral approach to breast cancer immunotherapy [J].

Arab, Atefeh ;

Behravan, Nima ;

Razazn, Atefeh ;

Barati, Nastaran ;

Mosaffa, Fatemeh ;

Nicastro, Jessica ;

Slavcev, Roderick ;

Behravan, Javad .

JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) :1257-1267

[4] Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care [J].

Ben-Aharon, Omer ;

Magnezi, Racheli ;

Leshno, Moshe ;

Goldstein, Daniel A. .

JAMA ONCOLOGY, 2018, 4 (03) :326-332

[5] A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. [J].

Bernstein, V. ;

Ellard, S. L. ;

Dent, S. F. ;

Tu, D. ;

Mates, M. ;

Dhesy-Thind, S. K. ;

Panasci, L. ;

Gelmon, K. A. ;

Salim, M. ;

Song, X. ;

Clemons, M. ;

Ksienski, D. ;

Verma, S. ;

Simmons, C. ;

Lui, H. ;

Chi, K. ;

Feilotter, H. ;

Hagerman, L. J. ;

Seymour, L. .

BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) :485-493

[6] Chemovirotherapy: combining chemotherapeutic treatment with onco-lytic virotherapy [J].

Binz, Eike ;

Lauer, Ulrich M. .

ONCOLYTIC VIROTHERAPY, 2015, 4 :39-48

[7] Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer [J].

Bramante, Simona ;

Koski, Anniina ;

Liikanen, Ilkka ;

Vassilev, Lotta ;

Oksanen, Minna ;

Siurala, Mikko ;

Heiskanen, Raita ;

Hakonen, Tiina ;

Joensuu, Timo ;

Kanerva, Anna ;

Pesonen, Sari ;

Hemminki, Akseli .

ONCOIMMUNOLOGY, 2016, 5 (02)

[8]

Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273

[9] Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus [J].

Cerullo, Vincenzo ;

Diaconu, Iulia ;

Kangasniemi, Lotta ;

Rajecki, Maria ;

Escutenaire, Sophie ;

Koski, Anniina ;

Romano, Valentina ;

Rouvinen, Noora ;

Tuuminen, Tamara ;

Laasonen, Leena ;

Partanen, Kaarina ;

Kauppinen, Satu ;

Joensuu, Timo ;

Oksanen, Minna ;

Holm, Sirkka-Liisa ;

Haavisto, Elina ;

Karioja-Kallio, Aila ;

Kanerva, Anna ;

Pesonen, Sari ;

Arstila, Petteri T. ;

Hemminki, Akseli .

MOLECULAR THERAPY, 2011, 19 (09) :1737-1746

[10] Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients [J].

Cerullo, Vincenzo ;

Pesonen, Sari ;

Diaconu, Iulia ;

Escutenaire, Sophie ;

Arstila, Petteri T. ;

Ugolini, Matteo ;

Nokisalmi, Petri ;

Raki, Mari ;

Laasonen, Leena ;

Sarkioja, Merja ;

Rajecki, Maria ;

Kangasniemi, Lotta ;

Guse, Kilian ;

Helminen, Andreas ;

Ahtiainen, Laura ;

Ristimaki, Ari ;

Raisanen-Sokolowski, Anne ;

Haavisto, Elina ;

Oksanen, Minna ;

Karli, Eerika ;

Karioja-Kallio, Aila ;

Holm, Sirkka-Liisa ;

Kouri, Mauri ;

Joensuu, Timo ;

Kanerva, Anna ;

Hemminki, Akseli .

CANCER RESEARCH, 2010, 70 (11) :4297-4309

← 1 2 3 4 5 6 7 8 9 10 →